TCMD Q2 2025: AfloVest Sales Surge 52%, Shifting Revenue Mix and Strategic Focus
AfloVest, airway clearance device, drove outsized growth as Tactile Medical’s revenue mix shifted toward faster-moving segments. Lymphedema business showed signs of stabilization, but basic pump mix weighed on top-line expansion. Management’s measured guidance raise and focus on operational leverage signal a cautious but constructive outlook as new salesforce and technology investments ramp.
Summary
- Airway Clearance Outperformance: AfloVest momentum accelerated, highlighting successful DME partnerships and education efforts.
- Salesforce and Tech Investments: CRM and AI adoption are now post-disruption, with productivity set to improve across territories.
- Guidance Caution: Management’s conservative outlook reflects ongoing product mix shifts and scaling complexities.
Performance Analysis
Tactile Medical delivered 7.8% year-over-year revenue growth in Q2, driven by a sharp 52% increase in airway clearance sales (AfloVest) to $12.9 million, while lymphedema revenue grew a modest 2% to $66 million. The lymphedema business, which still accounts for over 80% of total revenue, remains the company’s core, but the outperformance in airway clearance signals a meaningful shift in growth drivers. Gross margin improved to 74.5%, reflecting lower manufacturing and warranty costs and improved collections, even as operating expenses rose 13% on the back of technology and salesforce investments.
The company reported adjusted EBITDA of $7.7 million, down 15% year-over-year, as expected, due to planned spending. Stock buybacks and the retirement of a $24 million term loan further adjusted the balance sheet, with $81.5 million in cash remaining. Guidance for full-year revenue was nudged up at the low end, but management held a measured stance given lymphedema’s slower growth and ongoing salesforce scaling.
- AfloVest Drives Growth: Airway clearance now represents 16% of revenue, up from 11% a year ago, reflecting successful DME execution and market education.
- Basic Pump Mix Dampens Lymphedema Growth: Nimble, basic pump, outpaced market growth but carries lower ASP than FlexiTouch, muting revenue impact despite strong unit gains.
- Salesforce Expansion and CRM Stabilization: Headcount up 11% sequentially, with productivity expected to rise as new reps ramp and CRM/AI tools embed.
The company’s ability to balance strategic investments with margin preservation will be tested in the coming quarters, as the revenue mix continues to evolve and productivity initiatives mature.
Executive Commentary
"We delivered a strong performance this quarter, marked by total revenue growth of 7.8% year-over-year to 78.9 million, ahead of our previously stated Q2 expectations... Our growth and leverage strategies are in their execution phase, and we are increasingly confident in our ability to drive consistently improving results."
Sherry Dodd, Chief Executive Officer
"Second quarter operating expenses increased $6.5 million or 13% to $54.7 million... including and primarily driven by strategic technology investments. Operating income decreased $1.8 million or 30% to $4.1 million... We also completed an additional $16.5 million of stock buyback, which concludes the current stock repurchase program."
Elaine Berkemeyer, Chief Financial Officer
Strategic Positioning
1. Airway Clearance Emerges as a Growth Engine
AfloVest’s 52% sales surge was attributed to preferred product placement with top 10 respiratory DMEs (Durable Medical Equipment suppliers), expanded clinical education, and increased bronchiectasis awareness. Management’s focus on DME partnerships and education is yielding share gains, and the segment is closing in on market leadership. This success provides a counterbalance to slower lymphedema growth and diversifies revenue streams.
2. Lymphedema: Product Mix and Channel Strategy
Lymphedema revenue growth was muted at 2%, with Nimble, basic pump, outpacing both FlexiTouch and the overall market CAGR in unit terms. However, the shift toward basic pumps, which have lower average selling prices, is diluting revenue growth even as unit penetration improves. Channel strategy and new rep onboarding are designed to broaden penetration, with an emphasis on expanding into under-treated diagnosed patients and, longer-term, the undiagnosed population.
3. Technology and Operational Leverage
CRM stabilization and AI-driven workflow automation are central to management’s plan to scale efficiently. The CRM system is now past its disruptive phase, and new AI tools are being piloted to automate order intake and medical record review, aiming to reduce manual work and improve conversion speed. Productivity is measured by referrals per territory, with expectations for incremental improvement as the salesforce and patient services organization mature.
4. Reimbursement and Clinical Evidence Tailwinds
Reimbursement clarity improved post-Medicare NCD (National Coverage Determination) changes, allowing advanced pump access for patients with unique characteristics. Head and neck lymphedema clinical trial data is being disseminated, with commercial payer engagement underway. Policy updates are expected to unlock additional patient access, though the biggest P&L impact will likely come in 2026 and beyond.
5. Capital Allocation and Balance Sheet Flexibility
Share buybacks and term loan retirement demonstrate a commitment to shareholder returns and balance sheet strength. Management signals ongoing evaluation of strategic, accretive uses of capital as cash balances remain robust.
Key Considerations
This quarter marked a pivotal transition as Tactile Medical’s revenue mix shifted and operational investments matured. The company’s ability to drive margin expansion while scaling its commercial engine will be a key determinant of future value creation.
Key Considerations:
- Airway Clearance Momentum: AfloVest’s growth is sustainable if DME partnerships and education remain effective.
- Lymphedema Mix Headwind: Basic pump outperformance supports volume but weighs on revenue, requiring balanced channel execution.
- Salesforce Productivity Ramp: CRM and AI adoption should drive referral growth per territory as new hires mature.
- Reimbursement Policy Evolution: Medicare and commercial payer clarity could unlock additional patient cohorts, but timelines remain uncertain.
- Capital Deployment Discipline: Cash reserves and credit facility expansion provide optionality for future investments or M&A.
Risks
Execution risk remains around scaling new sales hires, particularly as productivity ramps and CRM/AI tools are embedded. Product mix shifts may continue to dilute top-line growth until advanced pump volumes stabilize. Reimbursement policy changes, while trending positive, are subject to payer-specific timelines and could delay access for key patient groups. Competitive intensity in both lymphedema and airway clearance markets persists, requiring ongoing innovation and partnership management.
Forward Outlook
For Q3 2025, management expects:
- Continued airway clearance outperformance, with AfloVest maintaining strong momentum
- Lymphedema growth to track closer to market as salesforce productivity improves
For full-year 2025, management raised guidance at the low end:
- Total revenue of $310 to $350 million, reflecting 6% to 8% growth
- Lymphedema revenue growth of 1.5% to 3%, airway clearance growth of 40% to 43%
Management highlighted several factors that inform the outlook:
- Salesforce expansion and new technology adoption are expected to drive incremental productivity in the back half
- Potential short-term variability from further AI tool rollouts and ongoing product mix shifts
Takeaways
Investors should focus on the company’s ability to translate operational investments into sustained margin and revenue growth, as revenue mix shifts and productivity initiatives mature.
- AfloVest’s outperformance validates the airway clearance strategy and diversifies growth drivers.
- Product mix headwinds in lymphedema are likely temporary, with stabilization expected as salesforce and channel strategies mature.
- Watch for signs of margin leverage and acceleration in referrals per territory, as CRM and AI tools are fully embedded and new reps ramp to full productivity.
Conclusion
Tactile Medical’s Q2 highlighted a successful pivot toward faster-growing segments, operational execution post-CRM disruption, and prudent capital allocation. Management’s cautious optimism and focus on scalable growth set the stage for further margin and revenue gains as technology and salesforce investments bear fruit.
Industry Read-Through
The strong AfloVest performance underscores the value of DME partnerships and provider education for medtech companies targeting chronic disease populations. As reimbursement clarity improves, companies with diversified portfolios and advanced workflow automation are better positioned to capture market share. Basic-to-advanced product mix dynamics and the importance of salesforce productivity ramp are relevant for peers in medical devices and durable medical equipment, while the shift toward digital and AI-driven operational leverage is becoming a competitive necessity across the sector.